This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Envair’s isolators prevent pharmacy and laboratory workers from dangerous exposure to cytotoxic drugs and ensure products are protected from microbiological contamination. Avideh Nazeri is vice president clinicaldevelopment, medical, and regulatory affairs, Novo Nordisk UK. A videh Nazeri.
The Company is in late-stage clinicaldevelopment and has been working toward establishing commercial readiness. The meeting will consist of presentations from the Company’s management team, with additional commentary from board members and collaborators, and will include a question and answer session for analysts and attendees.
MultiStem ® cell therapy is a patented regenerative medicine product candidate in clinicaldevelopment that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. About MultiStem ®.
The Current State of mRNA Analytics There isnt a lot of emphasis right now being put on new method development specifically for application to multivalent mRNA vaccines. And I think this is surprising given just how many multivalent mRNA vaccines are currently in clinicaldevelopment, begins Dr. Dawson.
As of January 31, 2024, approximately 131 unique RNA-based therapies are in clinicaldevelopment across various therapeutic areas. While these therapies span all stages of clinicaldevelopment, they are particularly concentrated in earlier phases, indicating strong future growth.
Below are some free webinars you can register for that have delved into the topic: Continuing Clinical Research Innovations After COVID-19. The Impact of COVID-19 on Early ClinicalDevelopment – What the New Landscape Will Look Like. Addressing the Rapidly Evolving Vaccine Development Landscape.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content